Replies to post #3240 on Statera BioPharma Inc (STAB)

[ssc]

Same thing was being said when stock was at 70 cents, then at 60 cents, then at 50 cents. Huge volume and down to 34 cents today. Company about to do more offerings at lower and lower prices, just as predicted. Also worried about losing NASDAQ listing.

Don't take my word for it, just read the company's own filings. From today (short version in red = massive dilution on the way):

Currently, our Common Stock trades on the Nasdaq Capital Market. During 2019 and 2020, we received notification from Nasdaq informing us of certain listing deficiencies related to the minimum required stockholders’ equity and minimum bid price listing requirements, which led to the issuance of delisting notices. Although we have since cured these deficiencies and our Common Stock continues to trade on the Nasdaq Capital Market, we have fallen out of compliance again since March 7, 2022 due to the closing bid price for our Common Stock for the preceding 30 consecutive business days being below the minimum $1.00 per share (“Minimum Bid Price Rule”) pursuant to Nasdaq Listing Rule 5550(a)(2). Although we have not received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market as of yet, it is likely we will receive one and it will provide a period of 180 calendar days to regain compliance with the Minimum Bid Price Rule. In order to regain compliance, we intend to obtain approval of our board of directors and shareholders of (i) a reverse stock split of the issued and outstanding shares of our common stock at a currently undetermined ratio to regain compliance with the Minimum Bid Price Rule and (ii) an increase of our authorized number of shares of common stock. Accordingly, we intend to issue a notice to our shareholders in the next 45 days to call for a shareholder meeting to obtain such approval. Even if we obtain approval and regain compliance, it is possible that we could fall out of compliance again in the future.

If we fail to maintain compliance with any Nasdaq listing requirements, our Common Stock could be delisted from the Nasdaq Capital Market. This could severely limit the liquidity of our Common Stock and your ability to sell the Securities on the secondary market.

We will need to raise additional capital in the future, and such funds may not be available on attractive terms, or at all.